Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Figure 1 | Arthritis Research & Therapy

Figure 1

From: Human rheumatoid arthritis tissue production of IL-17A drives matrix and cartilage degradation: synergy with tumour necrosis factor-α, Oncostatin M and response to biologic therapies

Figure 1

Over-expression of IL-17A in the human inflamed joint. IL-17A expression was measured by ELISA in serum (SRM) (a) from patients with inflammatory arthritis (IA; n = 40) vs. healthy controls (HC), (b) paired serums and synovial fluids (SF; n = 45), (c) synovial fluids from patients with inflammatory arthritis (n = 49) vs. osteoarthritis (OA) and (d) rheumatoid arthritis (RA; n = 11), psoriatic arthritis (PsA; n = 11) and OA (n = 3) synovial tissue lysates. (e) IL-17A-producing cells are detected in RA but not OA or healthy control synovium (E).

Back to article page